TFPI

TFPI

TFPI Molekülinformation

Molecule Name
Tissue factor pathway inhibitor
Molekülalias
TFPI,LACI,TFPI1,EPI,TFI
Drug Development Progress
Anzahl der klinischen Arzneimittel3
Anzahl der inverkehr gebrachten Arzneimittel2
Höchste Forschungs- und EntwicklungsphaseApproved
Target-Alias
TFPI,Tissue Factor Pathway Inhibitor,Extrinsic Pathway Inhibitor,TFPI1,LACI,EPI,Anti-Convertin,TFI,Lipoprotein-associated coagulation inhibitor,Tissue Factor Pathway Inhibitor (Lipoprotein-Associated Coagulation Inhibitor)
Molekülhintergrund
Tissue factor pathway inhibitor (TFPI) is also known as Extrinsic pathway inhibitor (EPI), Lipoprotein - associated coagulation inhibitor (LACI), is a plasma proteinase inhibitor synthesized by vascular endothelial cells and part of it is associated with glycosaminoglycans of these cells. TFPI is a single-chain polypeptide which can reversibly inhibit Factor Xa (Xa) and Thrombin (Factor IIa). TFPI is a secreted protein with a N­terminal acidic region, three Kunitz (K) domains separated with by two linker regions, and a C­terminal basic region. The first K domain inhibits coagulation factor VIIa complexed to tissue factor (TF); The second K domain inhibits factor Xa; The third K domain binds to heparin; The C­terminal basic region may have several functions. For example, it plays an important role in binding of TFPI to cell surfaces.

TFPI Produktliste

Species
  • Human(1)
Tag
  • His Tag(1)
Host
  • HEK293(1)
Conjugate
  • Unconjugated(1)
Grade
  • RUO(1)
Low Endotoxin
  • No(1)
MoleculeCat. No.Product NameArtHostStructurePurityActivitySize&PriceAdd to Cart
TFPI
Human TFPI Protein, His Tag (active enzyme)
Human
HEK293
SDS-PAGE
Enzyme

$320.00

50ug
You Have Viewed 1-1 Of 1 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Asset Licensing Opportunity
Resources

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
KN-057KN-057; KN057Phase 3 ClinicalSuzhou Alphamab Co Ltd
Hemophilia A; Hemophilia B
Details
MG-1113MG-1113; MG-1113APhase 1 ClinicalGC Biopharma Corp
Hemophilia A
Details
AP-017AP017; AP-017Phase 1 ClinicalAnyuan Pharmaceutical Technology (Shanghai) Co Ltd
Hemophilia A; Hemophilia B
Details

Inverkehr gebrachte Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaFrühestes MarkennameFrühestes GenehmigungslandFrüheste IndikationFrüheste GenehmigungsgesellschaftFrüheste GenehmigungsdatumIndikationenKlinische Studie
ConcizumabAnti-TFPI; mAb-2021; NNC-0172-2021; NNC-172-2021; mAbTFPI2021; NN-7415; NNC-0172-0000-2021ApprovedNovo Nordisk A/SAlhemoCanadaHemophilia BNovo Nordisk Canada Inc2023-04-17
Hemophilia A; Hemophilia B; Hemorrhage
Details
MarstacimabPF-6741086; PF-06741086ApprovedPfizer IncHYMPAVZI, 友瑞宁United StatesHemophilia A; Hemophilia BPfizer Inc2024-10-11
Hemophilia A; Hemophilia B; Hemorrhage
Details
Customer Reviews